Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiyue Granules is a Traditional Chinese Medicine (TCM) compound preparation developed by Shanghai Traditional Chinese Medicine University Yuanchuang Technology Co., Ltd. specifically for the treatment of chronic knee synovitis, often associated with knee osteoarthritis. The formulation is based on classical TCM principles aimed at clearing heat, resolving dampness, and activating blood circulation to alleviate joint swelling and pain. Pharmacological research indicates that Xiyue Granules exerts anti-inflammatory and chondroprotective effects by inhibiting the TLR4/NF-κB signaling pathway, which in turn reduces the production of pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α). Additionally, it has been shown to downregulate the expression of matrix metalloproteinases (MMPs), thereby mitigating the degradation of the synovial membrane and articular cartilage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiyue Granules.